News Daily News ‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials Michael O'Riordan February 20, 2025
News Daily News Olpasiran Cuts Lp(a) but Not Inflammatory Markers: OCEAN(a)-DOSE Yael L. Maxwell February 14, 2025
News Conference News THT 2025 Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity Todd Neale February 12, 2025
News Daily News Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab Michael O'Riordan February 05, 2025
News Features Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s? Michael O'Riordan January 17, 2025
News Daily News Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit Michael O'Riordan January 13, 2025
News Daily News CVD Risks Vary by Type of Menopausal Hormone Replacement Therapy Todd Neale December 04, 2024
News Conference News AHA 2024 ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS Michael O'Riordan November 21, 2024
News Conference News AHA 2024 ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH Caitlin E. Cox November 18, 2024
News Conference News AHA 2024 Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF Shelley Wood November 18, 2024
News Conference News AHA 2024 US Obesity Epidemic Continues to Skyrocket, With No End in Sight Michael O'Riordan November 15, 2024
News Daily News Many Patients Quit Taking GLP-1 Drugs: Understanding Why Is Key Todd Neale November 13, 2024
News Features GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix? Todd Neale November 13, 2024
News Daily News Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data Michael O'Riordan November 07, 2024
News Conference News TCT 2024 Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows Michael O'Riordan October 29, 2024
News Daily News Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime Michael O'Riordan October 14, 2024